Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 225.40M P/E - EPS this Y -226.30% Ern Qtrly Grth -
Income -118.86M Forward P/E -3.11 EPS next Y 40.30% 50D Avg Chg 26.00%
Sales 17.78M PEG - EPS past 5Y - 200D Avg Chg -55.00%
Dividend N/A Price/Book 4.39 EPS next 5Y - 52W High Chg -81.00%
Recommedations 2.30 Quick Ratio 8.15 Shares Outstanding 196M 52W Low Chg 64.00%
Insider Own 0.07% ROA -11.29% Shares Float 195.96M Beta 0.53
Inst Own 33.95% ROE -507.57% Shares Shorted/Prior 9.45M/15.20M Price 1.15
Gross Margin -63.49% Profit Margin - Avg. Volume 26,145,861 Target Price 2.25
Oper. Margin -173.92% Earnings Date Nov 8 Volume 14,309,020 Change -4.17%
Sesen Bio, Inc. News
10/22/21 26 Stocks Moving in Friday's Pre-Market Session
10/21/21 23 Stocks Moving in Thursday's Pre-Market Session
10/20/21 Mid-Afternoon Market Update: Nasdaq Turns Lower; Sesen Bio Shares Surge
10/20/21 32 Stocks Moving In Wednesday's Mid-Day Session
10/20/21 Sesen Bio Shares Gain On FDA Type A Meeting On Issues From Vicineum Response Letter
10/19/21 Why Sesen Bio Stock Is Trading Higher Higher During Tuesday's After-Hours Session
10/18/21 CLASS ACTION UPDATE for SESN, HYRE and SAM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
10/18/21 SESN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Sesen Bio, Inc. Investors With Losses Exceeding $400K of Class Action and Lead Plaintiff Deadline: October 18, 2021
10/18/21 SESN DEADLINE TODAY: Hagens Berman Alerts Sesen Bio (SESN) Investors to Today’s Lead Plaintiff Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys Now
10/18/21 SESN Final Deadline Today: Rosen, Global Investor Counsel, Encourages Sesen Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action - SESN
10/18/21 DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Sesen Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
10/18/21 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Sesen Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 18, 2021 - SESN
10/17/21 SESEN BIO 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Sesen Bio, Inc. - SESN
10/17/21 SESN FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Sesen Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action – SESN
10/17/21 DEADLINE ALERT for VIEW and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
10/17/21 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SESN, HYRE and APPH
10/17/21 SESN FINAL DEADLINE ALERT: Hagens Berman Encourages Sesen Bio (SESN) Investors with Significant Losses to Contact Firm's Attorneys Before OCT. 18TH LEAD PLAINTIFF DEADLINE in Securities Class Action
10/17/21 Sesen Deadline Alert
10/17/21 SESEN DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sesen To Contact Him Directly To Discuss Their Options

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

SESN Chatroom

User Image Lax76 Posted - 46 minutes ago

$SESN Merck running out of ways to prevent Sesen and Vicinium from getting to market. Keytruda sales will plummet

User Image DwimpleBean Posted - 1 hour ago

$SESN You think, EVEN the FDA can deny thousands of suffering patients a life extending therapy based on one poor investigator? An investigator that was fired immediately & who over saw only 4 trial patients? All of whom were not harmed by V! Get real. This is on the eve of approval.

User Image Sharnas1 Posted - 2 hours ago


User Image HFHInk Posted - 2 hours ago

$SESN See ya at .75..

User Image LiquidSignals Posted - 2 hours ago

LiquidTheta® Trade Alert (Delayed/Actionable) Ticker: $SESN Buy: May 20 2022 $2.00 Calls Entry Price: $0.20- $0.40 TP1: $0.24 TP2: $0.27 TP3: $0.30 Stop Loss: $0.17 (Optional) Highly Profitable Options Signals Delivered to Your Inbox

User Image steven1x Posted - 2 hours ago

$SESN Patient Demographics

User Image Kudbu Posted - 3 hours ago

$SESN the daily chart looks sketchy as fuck MM is a bitch lol if i didn’t have my feet in shib id be pissed

User Image Beltranc87 Posted - 3 hours ago

$SESN can we just get $4 and I’ll be a happy camper

User Image m8282 Posted - 3 hours ago

$SESN FV based on metrics Alone IMHO 1.25-1.35 Stated this for 2 months. CASH ALONE / PATENT / Drug still not getting much value currently /based on an approval at some point.....about 25 cents. CHINA -progression not even being factored ...Worth 2-3 dollars on an approval.....GETTING ZERO currently based on Positive Feedback / Minimal Remedy CMC 1.40-1.50 IF Later meeting in 4th qtr can Yield a RE-SUBMISSION in 2022 1st half < 2.00-2.50 KICKER- TOMMY BOY SHOULD SEEK PARTNER FOR HEAD AND NECK IMMEDIATELY< TOMMY BOY SHOULD ALSO DEMAND <<<< A RETRACTED STORY FROM BS STAT<<<<<<< or Face Defamation suit< 20 mil

User Image Stan003 Posted - 4 hours ago

$SESN my spider are tingling and telling me this will go under 1.00 on friday

User Image dp22 Posted - 4 hours ago

$SESN $BBIG $PROG Some days you’re the dick, some days you’re the asshole.

User Image KnightOfSESN Posted - 4 hours ago

$SESN Sesen Bio gearing up for CMC and clinical Type A meetings with the FDA! Chèrie Kaefring will be heading up operations as Director, Clinical Operations. Looking really promising! Bagholder with 94k shares at 0.90 average. Not selling till 7+. Looking forward to good news tomorrow. Hope everyone is having a blessed day. Take care bulls and KNIGHTS OF SESN!

User Image arnolddunn Posted - 4 hours ago

$SESN speculators will always speculate… why the outcome expected…doesn’t happen.

User Image keepMovingBullRun Posted - 4 hours ago


User Image TiTinvestor Posted - 4 hours ago

$SESN the true reason for CRL rejection was………to scoop up more shares at .7 🤣 some peps at FDAs actually missed buying at .54 …🤣 so to put CRL rejection out there would result in panic selling all the way down to .7🤣 now loaded and locked. .u will know soon that CRL is actually not big of a deal..😂 TITS APPROVED!! 😂🤣😂 mark me! 😂🤣

User Image Evein Posted - 4 hours ago

$SESN unqualified investigator has nothing to do with the Vicineum trials, but FDA still needs more clinical data and CMC fixed. FDA did not issue CRL because of just some unqualified investigator. They issued CRL because they just need more data.

User Image StockStrategists Posted - 4 hours ago

$SESN So how convenient this is just coming up before the meeting Friday? Will the meeting/review still happen and or matter?

User Image ReformedBull Posted - 4 hours ago

$SESN fda doesn’t care if drug works and can save lives. It’s a cesspool of corruption.

User Image TheBlinders Posted - 4 hours ago


User Image khickman Posted - 4 hours ago

$SESN REPOST khickman 8/18/21, 04:37 PM $SESN Problem with article is FDA is liable if accurate. 1. Why did not stop trial 2.Why did they accept NDA and not give Refuse to file 3. Why no advisory panel 4. WHY IS THIS NOT IN CRL PR. Something smells bad here

User Image je0922 Posted - 5 hours ago

$SESN The approval process was in effect put on pause by the CRL. If additional facts satisfy the questions stated in the CRL then the process would continue and response by the FDA would be need to be made on a schedule set by statute. There is no suggestion a new trial would be necessary. Look for approval sooner rather then later. Remember there is additional data available that could satisfy the requests of the FDA.

User Image ReformedBull Posted - 5 hours ago

$SESN the non compliant investigator sounds like a perfect plot from competition to detail sesn. Which means there is a lot of value..

User Image Strut Posted - 5 hours ago

$SESN So the FDA was told about the circumstances surrounding five patients in the trial and didn't say a word about it when it was originally discussed, then they used it as the reason for the CRL. Brilliant!!!

User Image ReformedBull Posted - 5 hours ago

$SESN buying more tomorrow

User Image Zengu Posted - 5 hours ago

$MKD This needs life! Should still be over the dollar mark. $SESN

User Image Quantisnow Posted - 5 hours ago

Top 3 SEC Filings on Quantisnow today: 1. $SESN 📜 Sesen Bio, Inc. filed SEC Form 8-K: Other Events: https://quantisnow.com/insight/1922680?s=qnps 2. $ACHR 📜 SEC Form EFFECT filed by Archer Aviation Inc.: https://quantisnow.com/insight/1918475?s=qnps 3. $PROG 📜 Progenity, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits: https://quantisnow.com/insight/1919114?s=qnps

User Image bentley99 Posted - 5 hours ago

$SESN Today's filing doesn't invalidate anything. Period.

User Image sweatheartkeroro Posted - 5 hours ago

$SESN triggered my stop loss...

User Image Xfactor41 Posted - 5 hours ago

$SESN Here's the TL;DR of the FDA's filing today: there was a physician whose license was suspended during one clinical trial that didn't inform SESN of said suspension. That's the reason for the CRL: an invalid clinical trial. The good news: it doesn't invalidate the entire drug, so it still may be viable. The bad news: this isn't a resolution that will be measured in days or weeks. Just saying "oh, it's now approved" will NOT happen. Best case scenario, the FDA says that the invalid trial would not have had bearing on the decision, they refile and get a new date 3 months out. Worst case scenario, the FDA says the trial's results would have bearing on the decision and that it or something comparable has to be re-conducted. This puts the timeframe in the 1-2 year range. In all likelihood, the time line will be somewhere between those two scenarios, but it ain't going to be before the end of the year.

User Image TeslamyLove Posted - 6 hours ago

$SESN “unusually large options trading” now we know why?

Analyst Ratings
HC Wainwright & Co. Neutral Aug 16, 21
Canaccord Genuity Buy Feb 17, 21
HC Wainwright & Co. Buy Feb 17, 21
H.C. Wainwright Buy Jun 11, 19
Jefferies Buy Jul 23, 18